Prediction of <i>mycoplasma hominis</i> proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology

Khan, Shahanavaj; Zakariah, Mohammed; Rolfo, Christian; Lembrechts, Robrecht; Palaniappan, Sellappan

doi:10.18632/oncotarget.8306

Cited by 37 publications

(24 citation statements)

References 85 publications

(101 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Various studies have shown that microbial alternations, characterized by a marked increase in the numbers of pathogens and a relative decrease in levels of beneficial bacteria, are connected with the development of gastrointestinal and extra-gastrointestinal cancers. [6][7][8][9][10][11][12][13] Altering the gut microbiota is expected as a novel method to deal with diseases associated with intestinal dysbiosis. Potential routes to target intestinal microbiota community include diet, probiotics, prebiotics, antibiotics and fecal microbiota transplantation (FMT).…”

Section: Introductionmentioning

confidence: 99%

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

207

147

View full text Add to dashboard Cite

The human gut is home to a large and diverse microbial community, comprising about 1,000 bacterial species. The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations with therapeutic intent has become a hot topic of cancer research, and the most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT) from healthy individuals to patients. FMT has demonstrated remarkable clinical efficacy against Clostridium difficile infection (CDI) and it is highly recommended for the treatment of recurrent or refractory CDI. Lately, interest is growing in the therapeutic potential of FMT for other diseases, including cancers. We briefly reviewed the current researches about gut microbiota and its link to cancer, and then summarized the recent preclinical and clinical evidence to indicate the potential of FMT in cancer management as well as cancer‐treatment associated complications. We also presented the rationale of FMT for cancer management such as reconstruction of intestinal microbiota, amelioration of bile acid metabolism, and modulation of immunotherapy efficacy. This article would help to better understand this new therapeutic approach for cancer patients by targeting gut microbiota.

show abstract

Section: Introductionmentioning

confidence: 99%

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

207

147

View full text Add to dashboard Cite

show abstract

“…Various factors are associated with the growth and development of cancer and PDAC, including mutation, age, sex, ethnicity, cigarette smoking, and viral and bacterial infections [5][6][7][8][9]. The association of infectious agents in the etiology of different types of cancer has piqued the interest of scientists in recent years.…”

Section: Introductionmentioning

confidence: 99%

“…The association of infectious agents in the etiology of different types of cancer has piqued the interest of scientists in recent years. Recent data have shown the involvement of Mycoplasma hominis, Chlamydia pneumoniae, and Escherichia coli infection in the etiology of prostate cancer, lung cancer, and colon cancer, respectively [9][10][11][12]. Recently, a wealth of previous studies have reported that microRNAs (miRNAs), a class of noncoding RNAs characterized by approximately 22 nucleotides in length, can inhibit the stability and translation of messenger RNAs (mRNAs) through binding to the specific sequence of genes, which are used as potential biomarkers for different kinds of cancer.…”

Section: Introductionmentioning

confidence: 99%

Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis

et al. 2019

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a class of the commonest malignant carcinomas. The present study aimed to elucidate the potential biomarker and prognostic targets in PDAC. The array data of GSE41368, GSE43795, GSE55643, and GSE41369 were downloaded from Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) and differentially expressed microRNAs (DEmiRNAs) in PDAC were obtained by using GEO2R, and overlapped DEGs were acquired with Venn Diagrams. Functional enrichment analysis of overlapped DEGs and DEmiRNAs was conducted with Metascape and FunRich, respectively. The protein–protein interaction (PPI) network of overlapped DEGs was constructed by STRING and visualized with Cytoscape. Overall survival (OS) of DEmiRNAs and hub genes were investigated by Kaplan–Meier (KM) plotter (KM plotter). Transcriptional data and correlation analyses among hub genes were verified through GEPIA and Human Protein Atlas (HPA). Additionally, miRNA targets were searched using miRTarBase, then miRNA–DEG regulatory network was visualized with Cytoscape. A total of 32 DEmiRNAs and 150 overlapped DEGs were identified, and Metascape showed that DEGs were significantly enriched in cellular chemical homeostasis and pathways in cancer, while DEmiRNAs were mainly enriched in signal transduction and Glypican pathway. Moreover, seven hub genes with a high degree, namely, V-myc avian myelocytomatosis viral oncogene homolog (MYC), solute carrier family 2 member 1 (SLC2A1), PKM, plasminogen activator, urokinase (PLAU), peroxisome proliferator activated receptor γ (PPARG), MET proto-oncogene, receptor tyrosine kinase (MET), and integrin subunit α 3 (ITGA3), were identified and found to be up-regulated between PDAC and normal tissues. miR-135b, miR-221, miR-21, miR-27a, miR-199b-5p, miR-143, miR-196a, miR-655, miR-455-3p, miR-744 and hub genes predicted poor OS of PDAC. An integrative bioinformatics analysis identified several hub genes that may serve as potential biomarkers or targets for early diagnosis and precision target treatment of PDAC.

show abstract

“…Several risk factors have been implicated in the pathogenesis of laryngeal cancer, including tobacco use, alcohol consumption, air pollution, genetics, nutrition, bacterial infection, life-style and occupational factors [ 5 – 9 ]. Moreover, more and more host genes, non-coding RNA targeting genes, transcription factors and enzymes have been involve in the whole complex processes of tumorigenesis and development of laryngeal cancer [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

TrkB promotes laryngeal cancer metastasis via activation PI3K/AKT pathway

et al. 2017

View full text Add to dashboard Cite

ObjectivesThe aim of our study was to investigate the role of TrkB pathway in tumor occurrence and development for in order to provide theoretical basis to laryngeal cancer therapy.Materials and methodsBiological characteristics of the cells were studied by migration tests and colony forming assay. Gene and protein expression analysis was performed by RT-PCR or western blot. in vivo experiments were conducted in syngeneic BALB/c mice.ResultsSignificant changes in protein and gene expression, including higher expression level of TrkB, were found in cells and laryngeal cancer specimens. we demonstrated that TrkB activates AKT via c-Src, leading to increased proliferation. Also, TrkB induced EMT via increased expression of EMT related transcription factors such as Twist-1 and Twist-2.ConclusionOur data indicate TrkB are overexpressed in laryngeal cancer, and TrkB signaling is involved in tumorigenicity of laryngeal cancer. These observations suggest that TrkB is a promising target for future intervention strategies to prevent tumor metastasis, EMT program in laryngeal cancer.What is already known about this subject?• Cancer of the larynx is one of the most common types of head and neck cancer.• The survival rate of advanced laryngeal cancer is only 30 to 40%.• The tropomyosin-related kinase B receptor (TrkB), together with TrkA and TrkC, are neurotrophin receptors regulating the proliferation and differentiation of neuronal cells.What are the new findings?• TrkB are overexpressed in laryngeal cancer.• TrkB signaling is involved in tumorigenicity of laryngeal cancer.• TrkB acts as a key regulator of the PI3K/AKT signal pathway-mediated tumor metastasis.How might these results change the focus of research or clinical practice?• These observations suggest that TrkB is a promising target for future intervention strategies to prevent tumor metastasis, EMT program in laryngeal cancer. Our study provides molecular insight into the tumor metastasis and has important implications in elucidating oncogenic processes.

show abstract

Prediction of mycoplasma hominis proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology

Cited by 37 publications

References 85 publications

Fecal microbiota transplantation in cancer management: Current status and perspectives

Fecal microbiota transplantation in cancer management: Current status and perspectives

Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis

TrkB promotes laryngeal cancer metastasis via activation PI3K/AKT pathway

Contact Info

Product

Resources

About